Targeting miR-155 to Treat Experimental Scleroderma
Scleroderma is a refractory autoimmune skin fibrotic disorder. Alterations of microRNAs in lesional skin could be a new approach to treating the disease. Here, we found that expression of miR-155 was up regulated in lesional skin tissue from patients with either systemic or localized scleroderma, an...
Main Authors: | Yan, Qingran, Chen, Jie, Li, Wei, Bao, Chunde, Fu, Qiong |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734331/ |
Similar Items
-
Corrigendum: Targeting miR-155 to Treat Experimental Scleroderma
by: Yan, Qingran, et al.
Published: (2016) -
Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma
by: Slezak-Prochazka, Izabella, et al.
Published: (2015) -
Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis
by: ZHENG, SHU-RONG, et al.
Published: (2012) -
miR-1, miR-10b, miR-155, and miR-191 are novel regulators of BDNF
by: Varendi, Kärt, et al.
Published: (2014) -
miR-155: A Novel Target in Allergic Asthma
by: Zhou, Hong, et al.
Published: (2016)